Trial Profile
Phase 2, randomized, open-label study to compare the efficacy and safety of siltuximab vs. corticosteroids in hospitalized patients with COVID19 pneumonia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Sep 2023
Price :
$35
*
At a glance
- Drugs Siltuximab (Primary) ; Lopinavir/ritonavir; Methylprednisolone
- Indications COVID 2019 infections; COVID-19 pneumonia
- Focus Therapeutic Use
- 15 Sep 2023 Status changed from recruiting to completed.
- 08 Jul 2020 According to European Clinical Trials Database record, this study is suspended in Spain.
- 16 Apr 2020 Status changed from not yet recruiting to recruiting.